Encapsulated cells producing cytochrome P450

1. A capsule comprising a porous membrane formed by a polyelectrolyte complex which encapsulates cells which express cytochrome P450 as a cell membrane-bound protein, wherein the porous membrane of the capsule is permeable to prodrug molecules and the cells are retained within the capsule.

2. The capsule according to claim 1 , wherein the capsule material comprises a complex formed from cellulose sulphate and polydimethyldiallylammonium.

3. The capsule according to claim 1 , wherein said capsule comprises cellulose sulphate.

4. The capsule according to claim 1 , wherein said capsule comprises polydimethyldiallylammonium.

5. The capsule according to claim 1 , wherein the capsule comprises a cellulose based material.

6. The capsule according to claim 1 , wherein the polyelectrolyte complex comprises a sulphate group.

7. A pharmaceutical composition comprising the capsule according to claim 1 .

8. The capsule according to claim 1 wherein the cytochrome P450 is cytochrome 2B1.

9. A method for ablation of tumour cells, comprising administering locally into said minor cells or close to the site of said tumor cells, prodrug molecules and a capsule wherein the capsule comprises a porous membrane formed by a polyelectrolyte complex which encapsulates cells which express cytochrome P450 as a cell membrane-bound protein, wherein the porous membrane of the capsule is permeable to the prodrug molecules, the cells are retained within the capsule, and the prodrug molecules are converted into active drug molecules by cytochrome P450 and thereby ablate the rumor cells.

10. A method of treating a tumor comprising administering to a subject in need thereof a therapeutically effective amount of a capsule and, either simultaneously or with a time span, a prodrug which is activated by cytochrome P450, wherein the capsule comprises a porous membrane formed by a polyelectrolyte complex which encapsulates cells which express cytochrome P450 as a cell membrane-bound protein, the porous membrane of the capsule is permeable to the prodrug cells are retained within the capsule and the capsule is introduced into the tumor or next to the tumor.

11. The method according to claim 10 , wherein the capsule is administered by a route of administration selected from the group consisting of: injection into the target cells, implantation into the target cells and combinations thereof, wherein the prodrug is administered systemically, locally or systemically and locally.

12. The method according to claim 10 , wherein the target cells are cells of breast tumours and/or pancreatic tumours.

13. The method according to claim 10 , wherein the prodrug is cyclophosphamide and/or ifosfamide.

14. A pharmaceutical kit comprising capsules according to claim 1 and a prodrug which is activated by cytochrome P450.

15. The pharmaceutical kit according to claim 14 , wherein the capsules and the prodrug are formulated so that the capsules, which are administered into a target or next to the target, and the prodrug can be adminstered by different routes of administration.

16. The pharmaceutical kit according to claim 15 , comprising the capsule in the form suitable for an injection or implantation into the target organs or next to the target organ, and the prodrug in the form suitable for systemic or local administration.

17. The pharmaceutical kit according to claim 14 comprising the capsules in the form suitable for the implantation into and/or next to breast cancer tissue or pancreatic cancer tissue.

18. The pharmaceutical kit according to claim 14 comprising cyclophosphamide and/or ifosfamide as the prodrug.

19. The method according to claim 9 wherein the prodrug is selected from the group consisting of cyclophosphamide and ifosfamide.

20. The capsule according to claim 8 wherein the cytochrome P450 2B1 is derived from rat liver.

21. The capsule according to claim 1 wherein the cytochrome P450 is encoded by a mammalian expression vector.